Table 4. Characteristics- of this cohort and a randomized clinical trial with glioblastoma multiforme treated with concomitant temozolomide and radiotherapy followed by adjuvant temozolomide.
| Variables | NCIC EORTC | Current study |
|---|---|---|
| Age (years) | 56 | 54 |
| Range | 19-70 | 36-78 |
| KPS Range | - | 80 50-100 |
| Sex | ||
| Male | 185 (64%) | 30 (60%) |
| Female | 102 (36%) | 20 (40%) |
| Surgery | ||
| Maximal | 113 (39%) | 30 (60%) |
| Partial | 126 (44%) | 16 (32%) |
| Biopsy | 49 (175) | 4 (8%) |
| Median survival | 14.6 | 17 |
| Median progression-free survival | 6.9 | 9 |
| 2-year overall survival | 26.5% | 37.7% |